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Abstract
Background:  RNA interference (RNAi)-mediated by the expression of short hairpin RNAs
(shRNAs) has emerged as a powerful experimental tool for reverse genetic studies in mammalian
cells. A number of recent reports have described approaches allowing regulated production of
shRNAs based on modified RNA polymerase II (Pol II) or RNA polymerase III (Pol III) promoters,
controlled by drug-responsive transactivators or repressors such as tetracycline (Tet)-dependent
transactivators and repressors. However, the usefulness of these approaches is often times limited,
caused by inefficient delivery and/or expression of shRNA-encoding sequences in target cells and/
or poor design of shRNAs sequences. With a view toward optimizing Tet-regulated shRNA
expression in mammalian cells, we compared the capacity of a variety of hybrid Pol III promoters
to express short shRNAs in target cells following lentivirus-mediated delivery of shRNA-encoding
cassettes.
Results: RNAi-mediated knockdown of gene expression in target cells, controlled by a modified
Tet-repressor (TetR) in the presence of doxycycline (Dox) was robust. Expression of shRNAs
from engineered human U6 (hU6) promoters containing a single tetracycline operator (TO)
sequence between the proximal sequence element (PSE) and the TATA box, or an improved
second-generation Tet-responsive promoter element (TRE) placed upstream of the promoter was
tight and reversible as judged using quantitative protein measurements. We also established and
tested a novel hU6 promoter system in which the distal sequence element (DSE) of the hU6
promoter was replaced with a second-generation TRE. In this system, positive regulation of shRNA
production is mediated by novel Tet-dependent transactivators bearing transactivation domains
derived from the human Sp1 transcription factor.
Conclusion: Our modified lentiviral vector system resulted in tight and reversible knockdown of
target gene expression in unsorted cell populations. Tightly regulated target gene knockdown was
observed with vectors containing either a single TO sequence or a second-generation TRE using
carefully controlled transduction conditions. We expect these vectors to ultimately find
applications for tight and reversible RNAi in mammalian cells in vivo.
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Background
During the past several years, RNAi-based approaches
involving small interfering RNAs (siRNAs) and shRNAs
have emerged as powerful tools to study gene function in
mammalian cells. These RNAs can be expressed intracellu-
larly by cloning shRNA-encoding templates into Pol II or
Pol III transcription units [1]. Pol III-based strategies are
ideally suited to express shRNAs due to the natural role of
Pol III to synthesize small RNAs with precisely defined
ends at very high levels, reaching up to 4 × 105 transcript
copies per cell [2].
For many applications, including transgenic approaches
involving genes whose inactivation is embryonically
lethal, it would be desirable to express shRNAs condition-
ally. Two general strategies have emerged allowing con-
trollable production of shRNAs in mammalian cells. The
first strategy is based on modified Pol II or Pol III promot-
ers, controlled by drug-responsive repressors or transacti-
vators such as Tet-dependent repressors or transactivators
[3-17], ecdyson-dependent transactivators [18] or the
HIV-1 Tat protein [19]. In an alternative strategy, the Cre-
lox recombination system was exploited to turn shRNA
synthesis on or off [20-22]. In contrast to the repressor/
transactivator-dependent systems, the effects of the Cre-
lox system lead to irreversible changes in the vector
genome.
Regulatable expression cassettes encoding shRNAs have
been delivered into mammalian cells by transient or sta-
ble transfection or by using viral vectors such as lentiviral
vectors. Alternatively, vectors based on oncogenic retrovi-
ruses or adenovirus-based vectors are being used [1,23]. It
is evident from the recent literature that the currently
available expression systems for regulated shRNA produc-
tion differ widely in terms of gene silencing efficiency and
control thereof. For example, to attain significant knock-
down of target gene expression using adenoviral vectors
encoding shRNAs corresponding to the c-myc coding
region, multiplicities of infection (MOI) up to 3000 were
used [10,11]. It is not clear whether the need for such high
MOIs was caused by poor transduction efficiencies or
ineffective shRNAs, or both.
Tet-regulatable lentiviral vectors encoding shRNAs were
first described by Wiznerowicz and Trono [6] and by Miy-
agishi et al. [9]. In the report by Wiznerowicz and Trono,
MOIs of at least 10 were used to attain efficient target gene
knockdown. In this case, MOIs were calculated based on
titers obtained by flow cytometric analysis (fluorescence
activated cell sorting, FACS) of vector-encoded EGFP
expression in HeLa cells. Given that measurements based
on FACS lead to an underestimation of vector titers, the
number of shRNA-encoding vector genomes per target cell
may have been up to 20-fold higher [24]. Miyagishi et al.
[9] observed robust knockdown of target gene expression
using lentiviral vectors at lower MOIs. However, this was
only observed following isolation of cell clones. However,
selection of cell clones is not always possible particularly
in the context of primary cells.
Recently, lentiviral vector systems bearing Tet-reponsive
Pol II promoters and shRNA-sequences embedded in a
microRNA context were described [14,17]. In these stud-
ies, transduced cells expressing high shRNA levels were
first enriched by FACS prior to determining the robustness
of shRNA-mediated knockdown of target gene expression
in such cells. Thus, the usefulness of these systems and
their background expression levels in unsorted cell popu-
lations remain to be determined.
In this study, we present quantitative data demonstrating
that, when the hU6 promoter is engineered to contain a
single TO sequence between the PSE and the TATA box, or
an additional second-generation TRE upstream of the pro-
moter, knockdown of target gene expression can be tightly
and reversibly repressed in the presence of a modified
TetR bearing a KRAB silencing domain. We also describe
the performance of a novel U6 promoter system in which
the DSE of the hU6 promoter was replaced with a second-
generation TRE. In this system, positive regulation of
shRNA production is mediated by a novel Tet-dependent
transactivator, rtTASp1(AB), bearing the transactivator
domains A and B of the human Sp1 transcription factor
[25].
Results
Design of improved lentiviral vectors for conditional, Dox-
dependent expression of shRNAs
Our goal was to design improved binary Tet-regulatable
lentiviral vector systems bearing Tet-responsive Pol III
promoters allowing tightly controlled and reversible
RNAi-mediated knockdown of target gene expression. To
accomplish this, lentiviral vectors were developed harbor-
ing Tet-regulatable hU6 promoters controlled either using
a chimeric TetR or Tet-dependent transactivators (Figure
1). Several TetR-responsive promoter constructs were
designed. In the Tet-hU6 construct, a 22-bp TO sequence
was placed between the PSE and the TATA box of the hU6
promoter (Figure 1A). In the TRE/TetU6 construct, a sec-
ond–generation TRE, lacking a TATA box and consisting
of eight repositioned TO sequences [26,27] was placed
upstream of the DSE (Figure 1A). For Dox-controlled pro-
duction of shRNAs from Tet-hU6 and TRE/TetU6 pro-
moter-bearing vectors, a lentiviral vector expressing a
chimeric TetR protein containing a KRAB-AB silencer
domain [28], referred to as Tet-tTS was developed (Figure
1B).BMC Biotechnology 2007, 7:41 http://www.biomedcentral.com/1472-6750/7/41
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In a second strategy, Tet-regulatable hybrid hU6 promot-
ers that responded to Tet-dependent chimeric transactiva-
tors were designed. In one such promoter construct,
referred to as PittΔU6, the hU6 DSE element that supports
Pol III transcription [29], was replaced using a second-
generation TRE lacking a TATA box (Figure 1A) to make it
responsive to Sp1-containing transactivators [30]. For
Dox-controlled production of shRNAs from the hybrid
PittΔU6 promoter, novel Tet-controlled reverse transacti-
vators bearing glutamine-rich transactivation domains
derived from the human Sp1 transcription factor were
constructed (Figure 1B). Hybrid rtTASp1 transcription fac-
tors bearing the Sp1 AB domain, the B domain or a trun-
cated B domain [31] fused to the DNA binding domain of
a reverse Tet-controlled transactivator (rtTA2s-M2) [32]
were developed. These transactivators are referred to as
rtTASp1(AB), rtTASp1(B) and rtTASp1(pB), respectively
(Figure 1B).
Knockdown of target gene expression in cells co-
transduced with lentiviral vectors containing the of Tet-
hU6 promoter and the Tet-tTS repressor
The ability of lentiviral vectors bearing the modified Tet-
hU6 promoter and of vectors bearing the unmodified
hU6 promoter to knock down EGFP target gene expres-
sion in HeLa G/R cells co-expressing EGFP and DsRed was
evaluated first. All virus stocks were adjusted based on tit-
ers determined by real-time PCR. Knockdown of EGFP
expression was analyzed by FACS. It was found that
knockdown of EGFP expression was efficient with the
unmodified hU6 promoter leading to a reduction in the
mean fluorescence intensity (MFI) of the EGFP-expressing
cell population below 15% of that seen in mock-infected
HeLa G/R cells (Figure 2). The Tet-hU6 and mU6 promot-
ers were found to be slightly less efficient at the same
MOIs, with the MFI levels reduced by some 80% and
70%, respectively relative to those seen in untransduced
HeLa G/R cells (Figure 2). When the shRNAs produced
from these promoters was modified to include six addi-
tional nucleotides at the 5' end, referred to as hU6 (+6)
and Tet-hU6 (+6) respectively, knockdown of EGFP
expression was reduced compared to that seen with the
unmodified constructs (Figure 2). In all cases, DsRed
expression levels were not impaired indicating that the
knockdown was specific.
Controlled knockdown of EGFP expression was investi-
gated next. To do this, HeLa G/R cells were co-transduced
with a constant amount of the shRNA-producing lentivi-
ral vector and variable amounts of the Tet-tTS lentiviral
vector. Half of these samples were cultured as normal; the
other half were cultured in the presence of Dox. Cells were
harvested 7 days after co-transduction, and EGFP expres-
sion was analyzed by flow cytometry. EGFP expression in
co-transduced cells was then compared to untransduced
cells (Figure 3A). It was found that EGFP expression was
tightly controlled in cells transduced with the Tet-hU6
vector at Tet-tTS MOIs of 25 and 50 by the inclusion or
exclusion of Dox in the culture medium. However, trans-
duction of the Tet-tTS vector at an MOI of 10 did not lead
to tight promoter shutoff in the absence of Dox. As
expected, a CXCR4-specific control shRNA did not cause
any decrease in EGFP levels with or without Dox. These
findings were then verified by Northern blot analysis of
Schematic representation of lentiviral vectors containing  modified U6 promoter sequences or Tet-dependent repres- sor and transactivator sequences Figure 1
Schematic representation of lentiviral vectors con-
taining modified U6 promoter sequences or Tet-
dependent repressor and transactivator sequences. 
(A) Promoters. DSE, distal sequence element; PSE, proximal 
sequence element; TO, tetracycline operator; TATA, TATA 
box; hU6, human U6 promoter; Tet-hU6, human U6 pro-
moter with an internal TO; TRE/TetU6, a second–generation 
TRE, lacking a TATA box and consisting of eight repositioned 
TO sequences placed upstream of the Tet-hU6 promoter; 
PittΔU6, hU6 promoter with DSE element deleted and 
replaced using a second-generation TRE lacking a TATA box. 
(B) Repressors and transactivators. PCMV, human cytomega-
lovirus immediate early promoter; TetR, tetracycline repres-
sor; KRABAB, KRAB-AB domain of the Kid-1 protein; rtTA, 
amino acids 1–207 derived from the Tet-controlled rtTA2S-
M2 reverse transactivator; Sp1-AB, Sp1-B and Sp1-pB, Sp1-
derived transactivation domains.
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RNA extracted from HeLa G/R cells co-transduced with
Tet-tTS and shRNA-expressing lentiviral vectors at MOIs of
25 each (Figure 3B). Quantitation of the blot revealed that
in the presence of Dox, EGFP mRNA levels in cells co-
transduced with Tet-hU6 and Tet-tTS decreased by as
much as 74% compared to untransduced cells.
To extend our studies, we next attempted to silence
expression of the human chemokine receptor CXCR4
gene in a controlled manner. To do this, shRNA-encoding
sequences containing 27-bp overlaps with the target
sequence [33] were cloned downstream of the Tet-hU6
and TRE/TetU6 promoters present in lentiviral vectors.
The ability of such lentiviral vectors encoding shRNAs cor-
responding to CXCR4 to silence CXCR4 expression in a
regulatable manner was assessed by determining CXCR4
protein levels.
To do this, HOS-CD4-Fusin cells that overexpress CXCR4
[34] were co-transduced with lentiviral vectors bearing
hU6, Tet-hU6 or TRE/TetU6 promoters to drive expres-
sion of shRNAs corresponding to CXCR4 mRNA and with
a Tet-tTS-expressing lentiviral vector at MOIs of 25 each.
Cells were cultured with or without Dox. After 6 days, a
flow cytometric analysis was carried out to determine the
CXCR4 levels in transduced cells compared to mock-
transduced HOS-CD4-Fusin cells (Figure 4). It was found
that knockdown of CXCR4 expression was very efficient.
There was a 89% ± 1.2%, 91% ± 2.3% and 88% ± 0.9%
Regulated silencing of EGFP expression in HeLa G/Rcells Figure 3
Regulated silencing of EGFP expression in HeLa G/
Rcells. (A) Control of shRNA expression, as determined by 
flow cytometry, based on the presence (yellow) or absence 
(blue) of Dox. HeLa G/R cells were co-transduced with a len-
tiviral-based silencing construct at an MOI of 25 and lentiviral 
vectors encoding the Tet-tTS repressor at MOIs varying 
from 10 to 50 as indicated. An shRNA corresponding to 
CXCR4 was used as a control. Results shown were taken 
from cells harvested 7 days posttransduction. (B) Northern 
blot analysis of 10 μg of total RNA isolated from HeLa G/R 
cells 7 days posttransduction. Sample 1: Mock control. Sam-
ples 2–6 were transduced with 25 MOIs of the lentiviral 
silencing constructs and 25 MOIs of the Tet-tTS repressor 
lentivirus. An shRNA corresponding to CXCR4 was used as 
a control (sample 6). RNA levels seen in the Northern blot 
were quantified by imaging of phosphor excitation. Results of 
quantification are shown in the graph. All levels represent the 
percentage of EGFP compared to the mock control (sample 
1) and are based on the EGFP:GAPDH RNA ratios.
12 3456 B
Promoter None Tet-hU6 hU6 Tet-hU6
shRNA None EGFP EGFP control
Dox - + - + - +
Test of U6 promoters in HeLa G/R cells Figure 2
Test of U6 promoters in HeLa G/R cells. Changes in 
relative EGFP expression levels in HeLa G/R cells determined 
by flow cytometry using lentiviral vectors encoding an 
shRNA corresponding to EGFP controlled by various U6 
promoters. For transduction, cells were exposed to 50 MOI 
(HOS cell units determined by real-time PCR). Expression 
levels are represented by MFI values of transduced cells com-
pared to mock transduced cells, which are referred to as 
percentage of control MFI. Results shown were taken 7 days 
posttransduction and represent the mean ± SD of at least 
three experiments. hU6, human U6 promoter; Tet-hU6, 
human U6 promoter with an internal TO; mU6, mouse U6 
promoter.BMC Biotechnology 2007, 7:41 http://www.biomedcentral.com/1472-6750/7/41
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decrease in the MFI of the cells following transduction
with lentiviral vectors bearing hU6, Tet-hU6 or TRE/TetU6
promoters, respectively. In the absence of Dox, CXCR4
receptor levels were unaltered indicating that repression
was tight. As expected, expression of the Tet-tTS repressor
alone did not affect CXCR4 receptor levels (Figure 4). In
agreement with the FACS data, there was a drop in CXCR4
mRNA levels in the presence of Dox but not in the absence
as determined by quantitative RT real-time PCR (data not
shown).
To show that knockdown of CXCR4 expression in HOS-
CD4-Fusin cells is reversible and to establish the kinetics
of knockdown, HOS-CD4-Fusin cells were transduced at
an MOI of 25 for both the Tet-tTS and shRNA-expressing
lentiviral vectors. The transduced cells were then
expanded in either the absence (Figure 5A) or the pres-
ence (Figure 5B) of Dox for 6 days, at which time Dox was
added to the cells previously grown in the absence of it
and removed from those previously grown in its presence.
The cells were analyzed for CXCR4 expression by flow
cytometry. This analysis revealed that, after 6 days of
growth in the absence of Dox, CXCR4 expression
decreased to almost 11 background levels within 3 days of
the addition of Dox (91% ± 0.2% for the Tet-hU6 pro-
moter and 85% ± 1.0% for the TRE/TetU6 promoter) (Fig-
ure 5A). However, after removal of Dox from the medium
of cells initially cultured in its presence, it took signifi-
cantly longer for CXCR4 expression to reach control levels
(105% ± 8.0% for the Tet-hU6 promoter and 100% ±
8.0% for the TRE/TetU6 promoter) (Figure 5B). This find-
ing suggests that intracellular Dox persisted for some time
after removal of Dox from the culture medium.
Positive control of Pol III promoter activity using novel Tet-
dependent transactivators
We next wanted to investigate a different approach allow-
ing conditional expression of shRNAs from Tet-responsive
Pol III promoters using novel Tet-dependent transactiva-
tors. To do this, HOS-CD4-Fusin cells were co-transduced
with an shRNA-encoding lentiviral vector containing the
Time course of CXCR4 knockdown Figure 5
Time course of CXCR4 knockdown. (A) HOS-CD4-
Fusin cells were co-transduced with lentiviral vectors as 
described in Figure 4. Transduced cells were incubated in the 
absence of Dox. On day 6, Dox was added to the culture 
medium, and cells were analyzed for CXCR4 receptor levels 
by flow cytometry at various times. (B) HOS-CD4-Fusin cells 
were co-transduced with lentiviral vectors as described in 
Figure 4. Cells were incubated in the presence of Dox for 6 
days. Dox in the culture medium was then removed and cells 
were analyzed for CXCR4 receptor levels by flow cytometry 
at various times.
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Regulated knockdown of CXCR4 chemokine receptor  expression in HOS-CD4-Fusin cells Figure 4
Regulated knockdown of CXCR4 chemokine recep-
tor expression in HOS-CD4-Fusin cells. Knockdown of 
cell surface CXCR4 expression was determined by flow 
cytometry following transduction of HOS-CD4-Fusin cells 
with lentiviral vectors expressing Tet-tTS, controlled by the 
CMV promoter and/or a CXCR4 shRNA, controlled by hU6 
promoters. Cells were incubated in the presence or absence 
of Dox for 6 days. CXCR4 receptor levels were determined 
by flow cytometry after incubation of the cells with PE-
labeled anti-human CXCR4 antibody. The results shown rep-
resent the mean ± SD of 3 experiments. They are displayed 
as the percentage of the MFI of mock-transduced cells.
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PittΔU6 promoter (see Figure 1A) and various rtTASp1
transactivator-encoding vectors (see Figure 1B) at an MOI
of 25 for each vector. The transduced cells were then incu-
bated in the presence of Dox for 7 days and then analyzed
by flow cytometry. The results presented in Figure 6 show
that knockdown of CXCR4 expression in cells transduced
with lentiviral vectors containing the PittΔU6 promoter-
CXCR4 shRNA expression cassette along with lentiviral
vectors encoding rtTASp1 transactivators was most effi-
cient with the rtTASp1(AB) transactivator. In this case,
CXCR4 expression decreased by 61% ± 2.4% (Figure 6)
while shRNAs expressed from a lentiviral vector bearing
an unmodified hU6 promoter led to a 82% drop at the
same MOI (data not shown). In contrast, when other
rtTASp1 transactivator-encoding vectors were used, silenc-
ing of the target gene was less pronounced. CXCR4 levels
dropped by 41% ± 1.4% and 34% ± 1.4% for the
rtTASp1(B) and rtTASp1(pB)-encoding vectors, respec-
tively. Silencing of CXCR4 expression resulting from
CXCR4 shRNAs was reversible. Five days after removal of
Dox, CXCR4 levels reached those observed with cells bear-
ing PittΔU6 promoter-CXCR4 shRNA cassettes alone (Fig-
ure 6). As expected, expression of the rtTASp1(AB)
transactivator alone did not change CXCR4 levels. How-
ever, in HOS-CD4-Fusin cells singly transduced with a
lentiviral vector bearing the PittΔU6 promoter-CXCR4
shRNA expression cassette, there was a 26% drop in
CXCR4 levels as judged by flow cytometry indicating that
the PittΔU6 promoter is leaky.
As expected, the MFI of cells co-transduced with a lentivi-
ral vector containing the PittΔU6 promoter-CXCR4
shRNA cassette and a lentiviral vector encoding the
rtTA2S-M2 transactivator [27] in the presence of Dox were
unaltered relative to mock-transduced cells (94% of mock
MFI). This is consistent with previous findings that trans-
activators containing Sp1 domains preferentially transac-
tivate Pol III-type promoters while VP16-domain-
containing transactivators preferentially interact with
mRNA-type promoters [30]. It was interesting to note
however, that binding of the rtTA2S-M2 transactivator to
the PittΔU6 promoter in the presence of Dox reduced the
promoter's leakiness (Figure 6). Reduced leakiness of the
PittΔU6 promoter-CXCR4 shRNA vector was also
observed in cells transduced with the Tet-tTS lentiviral
vector (data not shown). Thus, the leakiness observed
with the PittΔU6 promoter can be overcome by co-
expressing rtTASp1(AB) and Tet-tTS sequences in target
cells.
Discussion
Lentivirus-based vectors provide powerful tools for the
introduction of shRNA-encoding sequences into primary
cells, ES cells and embryos [35]. However, in general, only
a fraction of the transduced cells display detectable RNAi
at variable levels [21], indicating that the expression of
shRNAs from lentiviral vectors is affected by position
effects. This problem can in part be overcome by using
high enough MOIs to ensure multiple shRNAencoding
cassettes per genome. Among those cassettes, some are
expected to escape position-dependent effects, resulting in
sustained shRNA expression. Alternatively, isolated cell
clones obtained by FACS sorting of transduced cell popu-
lations can be used to increase the robustness of shRNA-
mediated gene knockdown [9,14,17,36]. Unfortunately,
selection of cell clones is not always possible particularly
in the context of primary cells. More importantly, selec-
tion strategies are in general not feasible in vivo.
To characterize our lentiviral vector system for its capacity
to conditionally knock down gene expression, we chose
the EGFP transgene as a target for our initial investigation.
It was found that silencing of EGFP protein and mRNA
production was repressed quantitatively in the absence of
Dox provided that a high enough MOI of the two vectors
was used. It was also found that in contrast to the findings
reported by Lin et al. [12], our single-copy TO configura-
tion allowed tightly regulated EGFP knockdown. The
improved performance of our system compared to that
reported by Lin et al. may be related to the fact that a TetR
bearing the potent KRAB silencing domain was used in
our work. In contrast, Lin et al. used an unmodified TetR.
To fully validate the two systems, it will ultimately be nec-
Positive regulation of Pol III promoter activity using Dox- dependent transactivators bearing Sp1 transactivation  domains Figure 6
Positive regulation of Pol III promoter activity using 
Dox-dependent transactivators bearing Sp1 transac-
tivation domains. HOS-CD4-Fusin cells were co-trans-
duced with a lentiviral vector expressing an shRNA 
corresponding to CXCR4 from the PittΔU6 promoter and 
lentiviral vectors encoding the rtTASp1(AB), rtTASp1(B), or 
rtTASp1(pB) transactivator, or the rtTA2s-M2 transactivator. 
Transduced cells were expanded in the presence of Dox for 
7 days. Dox was then removed and cells were analyzed by 
flow cytometry at the times indicated. The results shown are 
representative of 3 similar experiments performed.
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essary to compare shRNA levels in transduced cells in the
presence and absence of Dox using Northern blot experi-
ments.
As a second target, we chose the CXCR4 chemokine recep-
tor gene. In our Tet-regulatable lentivirus system, robust
CXCR4 knockdown was observed in unsorted cell popu-
lations at MOIs of 25. The excellent performance of our
system may be due in part to the design of the shRNAs. It
was recently reported that synthetic dsRNAs and shRNAs
longer than 19–21 bp were able to more efficiently enter
the RNAi pathway and to knock down the target gene
without causing nonspecific effects [33,38]. Based on
these findings, we used CXCR4-specific shRNAs, 27 nt in
length.
It is evident from Figures 2 and 3 that insertion of a single
TO sequence upstream of the TATA box had only a minor
effect on the performance of the Tet-hU6 promoter. Also,
the experiments presented in Figures 4 and 5 show that
RNAi mediated by the Tet-hU6 and TRE/TetU6-contain-
ing vectors was tight in the absence of Dox. This indicates
that the two systems performed equally well as far as
HOS-CD4-Fusin cells are concerned.
The position of the TRE element appears to influence
background expression. Recent evidence presented by
Zhou et al. [39] has shown that the distance between the
TRE element and the promoter sequence is important as
far as Pol II promoters are concerned. TRE elements
placed in close proximity to a Pol II promoter sequence
displayed lower background expression compared to TRE
elements placed farther away within the viral LTRs. It
remains to be determined whether the same is true for Pol
III promoters.
With a view toward designing Pol III promoters that
respond to Tet-dependent transactivators, we developed
an alternative Tet-dependent lentiviral vector system. In
this system, novel Dox-dependent transactivators consist-
ing of Sp1 transcription factor transactivation domains
fused to a truncated version of the rtTA2S-M2 protein lack-
ing the VP16 transactivation domain were expressed from
lentiviral vectors. Expression of shRNA is achieved from a
hybrid U6 promoter lacking the DSE. Using this system,
Dox-dependent knockdown of CXCR4 expression was
clearly evident as shown in Figure 6. However, there was
background expression in the absence of the transactiva-
tor and/or Dox. Interestingly, cells co-transduced with a
lentiviral vector bearing the PittΔU6/shRNA-encoding
sequences and a second lentiviral vector encoding the
rtTA2S-M2 transactivator in the presence of Dox displayed
lower background expression possibly due to the fact that
the rtTA2S-M2 transactivator blocked Pol III activity.
Reduced background expression was also observed in cells
bearing the Tet-tTS repressor (data not shown). It is con-
ceivable that cells displaying lower background expres-
sion could also be isolated by FACS sorting or drug
selection. Such a strategy was used by Gupta et al. [18] to
isolate ecdyson-inducible cell clones expressing shRNA
from hybrid RNA Pol III promoters in response to a GAL4-
Oct2Q(Q→A) transactivator. While this manuscript was
in preparation, Amar et al. [40] described a regulatable
lentiviral vector system containing a hybrid transactivator
consisting of the Oct2Q(Q→A) transactivation domain
fused to the rtTA2S-M2 DNA binding domain and a U6
core promoter preceded by 7 TO sequence. Similar to our
system, this system was found to be leaky in the absence
of Dox. However, isolated clones displayed low back-
ground expression and robust inducibility.
For tight and reversible RNAi in vivo, it would be desirable
to have combined vectors available harboring Tet-
dependent repressors or transactivators as well as shRNA-
encoding sequences. Attempts to generate such vectors
have been reported by others [36,40]. However, these vec-
tors appear to be leaky.
Conclusion
We provide quantitative data suggesting that robust and
tightly regulated knockdown of gene expression can be
obtained using lentiviral vectors bearing either a single TO
sequence or a second-generation TRE in transduced cell
populations without the need for sorting cell clones.
Methods
Cell lines
Cell lines used included human embryonic kidney 293 T
cells (ATCC, CRL-11268) [41], human osteosarcoma
(HOS) cells (ATCC, CRL-1543), HOS-CD4-Fusin cells
(provided by Dr. Nathaniel Landau through the NIH
AIDS Research and Reference Reagent Program, German-
town, MD) [34] and HeLa cells (ATCC, CCL-2). HeLa cells
co-expressing EGFP and DsRed (referred to as HeLa G/R
cells) were generated by co-transduction of HeLa cells
with NL-CMV/EGFP and NL-CMV/DsRed lentiviral vec-
tors [42]. Cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) (Gibco, Grand Island, NY) and
supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (HyClone, Logan, UT).
Construction of lentiviral vectors
The hU6 promoter was amplified from HeLa cell DNA by
polymerase chain reaction (PCR) as described [43] and
cloned into the EcoRI and XbaI sites of pUC19 to yield
pUC-U6. To generate a wild-type hU6 promoter and a
hU6 promoter harboring the TO sequence with an ApaI
site for cloning of shRNA, the following mutually priming
oligonucleotides were used: WT sense (5'-
CATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTT-BMC Biotechnology 2007, 7:41 http://www.biomedcentral.com/1472-6750/7/41
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GGCTTTATATATCTTGTGGAAAGGACGAA ACACCG-3'),
Tet sense (5'-CATATGCTTACCGTAACTTGAAAGTACTC-
TATCATTGATAGAGTTATATATCT TGTGGAAAGGAC-
GAAACACC-3'), and antisense (5'-
TCTAGACTCGAGAATAGTGTTGTGTGCCTAGGATATGT-
GCTGCCGAAGCGGG CCCGGTGTTTCGTCCTTTC-
CACAA-3'). Annealed oligonucleotides were filled in
using the Sequenase v. 2.0 DNA polymerase (USB, Cleve-
land, OH) and subsequently were cloned into the NdeI
and XhoI sites of pUC-U6, resulting in pUC-hU6 (+6) and
pUC-Tet-hU6 (+6), respectively. To move the ApaI site
immediately upstream of the start of transcription (posi-
tion +1), a PCR was performed using a sense primer (5'-
CGCCAGGGTTTCCCAGTCACGAC-3') and a mis-
matched antisense primer (5'- TCTAGACTCGAG-
GGGCCCTCGTCCTTTCCACAAGATATAT-3'). The
resulting fragments were cloned into pUC19 to yield
pUC-Tet-hU6 and pUC-hU6. To construct a derivative of
the Tet-hU6 promoter harboring an upstream TRE, a 300-
bp PCR fragment containing a TRE/Pitt promoter
sequence [26,27] lacking a TATA box sequence was PCR
amplified using pNL-TRE/Pitt-EGFPΔU3 DNA [27] as a
template. The following primers were used: sense primer
(5'-CCGATGATATCAAGTGCCACCTGACGTCTCCCTA-
3') and antisense primer (5'- TCGTGGCTAGCCTCTAT-
CACTGATAGGGAGCTCG-3'). The resulting PCR frag-
ment was first cloned into the pCR4-TOPO plasmid
(Invitrogen, Carslbad, CA), resulting in the pCR-TRE plas-
mid. The insert fragment was cut out using EcoRI and sub-
sequently ligated into the unique EcoRI site present in
pUC-Tet-hU6, generating the pUC-TRE/Tet-U6 plasmids.
A truncated version of the U6 promoter containing a TRE
sequence replacing the DSE element was constructed as
follows: A 695-bp PCR fragment was prepared using a
sense primer (5'-GATCCGCTAGCGCTGTTAGAGAGA-
TAATTAG-3') and an antisense primer (5'-
GTCAGCACTAGTGGTACCCGGAGCCTAT-
GGAAAAACG-3') and plasmid pUC- hU6 as a template.
The resulting PCR fragment containing a U6 promoter
lacking the DSE sequence was subcloned into the pCR-
TRE plasmid using the NheI and SpeI sites, resulting in
pPittΔU6.
To introduce an shRNA-encoding cassette downstream of
the U6 promoter sequence, mutually priming oligonucle-
otides corresponding to the EGFP sequence were cloned
into the ApaI and XhoI sites of the various plasmids bear-
ing hU6 or Tet-hU6 promoter sequences or the murine U6
(mU6) promoter which was derived from the
pSilencer1.0 plasmid (Ambion, Austin, TX). Sequences
corresponding to CXCR4 were cloned downstream of the
hU6, Tet-hU6, TRE/TetU6 and PittΔU6 promoters. The
sequences of the mutually priming oligonucleotides used
were as follows: EGFP sense (5'- GGGCCCGCAAGCT-
GACCCTGAAGTTCcttcctgtcaGAACT-3'), EGFP antisense
(5'- CTCGAGAAAAAAGCAAGCTGACCCTGAAGTTCt-
gacaggaagGAACT-3'), CXCR4 sense (5'-
CGGATCAGTATATACACTTCAGATAACTaagttctctAGT-
TATCTGAAGTGTATATACTGATCCTTTTTC-3'), and
CXCR4 antisense (5'-
TCGAGAAAAAGGATCAGTATATACACTTCAGATAACTa-
gagaacttAGTTATCTGA AGTGTATATACTGATCCGGGCC-
3'). The lowercase letters in these sequences refer to the
loop sequence in the resulting hairpin RNA, whereas the
capital letters represent the sequences corresponding to
the target mRNA. The sequence targeting EGFP mRNA is
19 nucleotides (nt) long and the sequence targeting
CXCR4 is 27 nt long. The promoters and shRNA-encoding
cassettes of the resulting plasmids were sequenced to ver-
ify fidelity.
To create lentiviral vectors bearing U6 promoter-shRNA
cassettes, sequences were excised from the pUC backbone
using EcoRI, blunted using T4 DNA polymerase (New
England Biolabs, Beverly, MA), and cleaved using XhoI.
This fragment was cloned into the HpaI and XhoI sites of
the pNL-EGFP/CMV lentiviral vector [44,45]. To create
lentiviral vectors bearing the TRE/TetU6 promoter-shRNA
cassette, sequences were excised from the pUC-TRE/Tet-
U6 backbone using EcoRV and PstI, and blunted using T4
DNA polymerase. This fragment was then cloned into the
HpaI and XhoI (blunted) sites of the pNL-EGFP/CMV len-
tiviral vector. In order to obtain lentiviral vectors bearing
the PittΔU6 promoter-shRNA cassette, the corresponding
sequences were excised from pPittΔU6 using EcoRV and
KpnI and ligated into the HincII/KpnI site of pNL-EGFP/
CMV.
Plasmid pNL-rtTA2S-M2 containing the rtTA2s-M2 trans-
activator sequence controlled by the constitutive human
CMV-IE promoter was described previously [27]. A lenti-
viral plasmid encoding the chimeric Tet-tTS TetR [28] was
generated as follows: pTet-tTS (Clontech, Palo Alto, CA)
was cut using ClaI, blunted, and then cut using XbaI. The
resulting 850-bp fragment was ligated into the XbaI and
BamHI (blunted) sites of the pNL-rtTA2S-M2 lentiviral
vector [27] to yield pNL-Tet-tTS. Lentiviral vectors encod-
ing three variants of the rtTASp1 transactivator were gen-
erated as follows: A 1250-bp fragment encoding the
glutamine-rich A and B domains (amino acids 80–485) of
the Sp1 transcription factor [25,31,46] was PCR amplified
using a sense primer (5'- attgtcgatatcggccggaggaggatcccag-
ggcccgagtcagtca-3') and an antisense primer (5'- agataac-
ccgggtgctaaggtgattgtttgggcttgt-3'). A 690-bp fragment
encoding the Sp1 B domain (amino acids 263–485) was
PCR amplified using a sense primer (5'attgtcgatatcggccg-
gaggaggatccatcaccttgctacctgtcaa-3') and the same anti-
sense primer as before. Finally, a 290-bp fragment
encoding the C-terminal part (amino acids 398–485) of
the Sp1 domain B was PCR amplified using a sense primerBMC Biotechnology 2007, 7:41 http://www.biomedcentral.com/1472-6750/7/41
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(5'attgtcgatatcggccggaggaggatctcttatccagcctcagctagt-3')
and the same antisense primer as before. In all cases, tem-
plate DNAs for PCR were prepared by reverse transcrip-
tion of human total RNA (Human Control RNA, Applied
Biosystems). The PCR fragments were cloned into the
pCR4-TOPO plasmid (Invitrogen). The resulting plasmids
were cut with XmaI and EagI and sequences encoding Sp1
domains were used to replace a 116-bp XmaI/EagI frag-
ment present in pNL-rtTA2s-M2 resulting in plasmids
pNL-rtTASp1(AB), pNL-rtTASp1(B), and pNL-
rtTASp1(pB), respectively.
Production and titration of lentiviral vectors
Lentiviral vector preparations were generated by calcium
phosphate-mediated transfection of 293 T cells with mod-
ifications as described [47,48]. Vector stocks were titrated
using HOS cells. Cells in six-well plates were transduced
with viral vector stocks for 16 h in the presence of 8 μg/ml
polybrene. After 16 h, virus-containing medium was
removed and replaced with 2 ml of fresh medium. DNase
I (Sigma, St. Louis, MO) was added 48 h later directly to
the cell culture medium at a final concentration of 2.5 U/
ml. After incubation at 37°C for 30 min, the cells were
trypsinized, and the genomic DNA as harvested using a
DNeasy kit (Qiagen, Valencia, CA). Real-time PCR was
then used to quantify the proviral DNA. A primer-probe
set corresponding to the viral gag region was used as pre-
viously described [27,49]. In parallel, a primer-probe set
specific for RNase P (Applied Biosystems) was used to
quantify the genomic DNA. Standard curves were gener-
ated for RNase P using serial dilutions of total human
DNA (Applied Biosystems). The standard curves for gag
were generated by serially diluting the pNL-EGFP/CMV
plasmid DNA quantified using the Fluorescent DNA
Quantification Kit (Bio-Rad Laboratories, Hercules, CA).
In all experiments, 1 × 105 cells were transduced for 16 h
in the presence of 8 μg/ml polybrene. The MOIs used are
indicated in the Results section. When applicable, Dox
was added to the cells at the times indicated at a final con-
centration of 1 μg/ml.
Analysis of EGFP and CXCR4 expression by flow cytometry
Transduced cells expressing EGFP were trypsinized and
collected and washed twice with PBS containing 2% FBS
and analyzed by FACS [50]. For antibody staining,
trypsinized cells were resuspended in PBS/2% FBS con-
taining phycoerythrin-labeled anti-human CXCR4 mono-
clonal antibody (Clone 12G5, R&D Systems, Inc.,
Minneapolis) and incubated for 1 h at room temperature.
Cells were washed twice with PBS/2% FBS and analyzed
by FACS.
Northern blotting of cellular RNA
Total RNA was isolated from HeLa G/R cells using Trizol
reagent (Invitrogen, Carlsbad, CA). RNA (10 μg) was blot-
ted and probed for EGFP and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) sequences. Northern blot anal-
ysis was done as described before [27].
Quantitative reverse-transcriptase real-time PCR
Total RNA was isolated from HOS-CD4-Fusin cells using
Trizol reagent (Invitrogen). For one-step reverse-tran-
scriptase real-time PCR (RT real-time PCR), 50 ng of total
RNA per reaction was used. Reactions were performed as
described in the Applied Biosystems protocol for one-step
RT real-time PCR. To quantify CXCR4 mRNA levels, a
commercially available primer-probe set (FAM labeled)
was used (TaqMan Gene Expession Assays,
HS00237052m1, Applied Biosystems). To quantify the
levels of the reference GAPDH mRNA, a target-specific
primer-probe set (VIC labeled) was used (Human Endog-
enous Controls, catalog number: 4310884E, Applied Bio-
systems). Reactions were performed using the Mx3000P™
Real-Time PCR System (Stratagene).
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